Canada Mrna Therapeutics Contract Development & Manufacturing Market Size & Outlook

The mrna therapeutics contract development & manufacturing market in Canada is expected to reach a projected revenue of US$ 425.2 million by 2030. A compound annual growth rate of 11% is expected of Canada mrna therapeutics contract development & manufacturing market from 2024 to 2030.
Revenue, 2023 (US$M)
$205.4
Forecast, 2030 (US$M)
$425.2
CAGR, 2024 - 2030
11%
Report Coverage
Canada

Canada mrna therapeutics contract development & manufacturing market, 2021-2030 (US$M)

Canada

Related Markets

Canada mrna therapeutics contract development & manufacturing market highlights

  • The Canada mrna therapeutics contract development & manufacturing market generated a revenue of USD 205.4 million in 2023 and is expected to reach USD 425.2 million by 2030.
  • The Canada market is expected to grow at a CAGR of 11% from 2024 to 2030.
  • In terms of segment, infectious diseases was the largest revenue generating indication in 2023.
  • Infectious Diseases is the most lucrative indication segment registering the fastest growth during the forecast period.


Mrna therapeutics contract development & manufacturing market data book summary

Market revenue in 2023USD 205.4 million
Market revenue in 2030USD 425.2 million
Growth rate11% (CAGR from 2023 to 2030)
Largest segmentInfectious diseases
Fastest growing segmentInfectious Diseases
Historical data2021 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationInfectious Diseases
Key market players worldwideDanaher Corp, Kaneka Corp, TriLink BioTechnologies, Apex Biotechnology, BioNTech SE ADR, Lonza Group Ltd, Nunn’s Home Medical Equipment, EQT Corp, Catalent Inc, Samsung Electronics Co Ltd, Biomay AG, Indication, eTheRNA immunotherapies, BioCina


Other key industry trends

  • In terms of revenue, Canada accounted for 5.0% of the global mrna therapeutics contract development & manufacturing market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In North America, U.S. mrna therapeutics contract development & manufacturing market is projected to lead the regional market in terms of revenue in 2030.
  • U.S. is the fastest growing regional market in North America and is projected to reach USD 2,802.8 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

MRNA Therapeutics Contract Development & Manufacturing Market Scope

Mrna therapeutics contract development & manufacturing market segmentation & scope

MRNA Therapeutics Contract Development & Manufacturing Market Companies

Name Profile # Employees HQ Website

Canada mrna therapeutics contract development & manufacturing market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mrna therapeutics contract development & manufacturing market will help companies and investors design strategic landscapes.


Infectious diseases was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Canada mrna therapeutics contract development & manufacturing market based on infectious diseases covering the revenue growth of each sub-segment from 2021 to 2030.


The development of mRNA therapeutics is increasing in Canada as companies are increasingly inclined toward investing in clinical trials. For instance, in June 2022, the Government of Canada announced an agreement with Moderna to produce mRNA vaccines in Canada.

This agreement began in 2021, during the COVID-19 pandemic, as the country faced intense global competition to secure vaccines. Furthermore, in February 2024, Moderna announced the completion of its mRNA vaccine production facility in Laval, Quebec.

Similarly, in October 2022, Providence Therapeutics Holdings, Inc. announced positive top-line data from the PRO-CL-002 Phase 2 study evaluating the tolerability, safety, and immunogenicity of its PTXCOVID19-B, a mRNA COVID-19 vaccine candidate. The company initiated a Phase 3 trial in a booster setting based on immunogenicity and positive safety results.

Reasons to subscribe to Canada mrna therapeutics contract development & manufacturing market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Canada mrna therapeutics contract development & manufacturing market databook

  • Our clientele includes a mix of mrna therapeutics contract development & manufacturing market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Canada mrna therapeutics contract development & manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Canada mrna therapeutics contract development & manufacturing market from 2021 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Canada mrna therapeutics contract development & manufacturing market size, by indication, 2021-2030 (US$M)

Canada MRNA Therapeutics Contract Development & Manufacturing Market Outlook Share, 2023 & 2030 (US$M)

Canada mrna therapeutics contract development & manufacturing market size, by indication, 2021-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more